


Review **Open Access**

Challenges of Localization Requirements for Medical Device Manufacturers and Strategic Responses

Jiguang Liu ^{1,*}, Dhakir Abbas Ali ¹ and Zheyuan Liu ²



¹ Faculty of Business and Accountancy, Lincoln University College, Malaysia

² College of Water Conservancy and Civil Engineering, Shandong Agricultural University, Tai'an, Shandong, China

* Correspondence: Jiguang Liu, Faculty of Business and Accountancy, Lincoln University College, Malaysia

Abstract: As the medical device industry becomes increasingly globalized, manufacturers are facing significant challenges arising from localization requirements imposed by different countries. These requirements, while designed to foster domestic manufacturing and economic growth, create complexities in terms of regulatory compliance, cost structures, supply chain management, and intellectual property risks. This paper reviews the challenges associated with localization in the medical device sector, highlighting key issues such as regulatory complexity, rising costs, and the risks associated with protecting intellectual property. It further explores strategic responses employed by companies, including building local partnerships, investing in local research and development, leveraging digital technologies, and engaging in policy advocacy. The paper draws on successful case studies from companies such as Philips Healthcare, Medtronic, and Siemens Healthineers to provide actionable insights for companies looking to navigate the localization landscape. The findings emphasize the importance of a strategic, flexible approach to localization in order to ensure global competitiveness while complying with local regulations.

Keywords: medical devices; localization; supply chain management; global strategy; market access

Received: 10 April 2025

Revised: 16 April 2025

Accepted: 06 May 2025

Published: 08 May 2025



Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

In recent years, the globalization of the healthcare industry has led to an increasing demand for medical devices across diverse markets. As countries seek to boost domestic manufacturing capabilities and ensure the availability of medical devices that meet local standards, many have introduced localization requirements for manufacturers. These requirements typically mandate that medical devices be produced or assembled locally, subject to local regulations, or adapted to meet specific national standards. Such policies aim to promote economic growth, enhance local industry capabilities, and ensure that healthcare systems are supported by locally available products.

Despite the potential benefits of these requirements, they present significant challenges for medical device manufacturers, particularly those operating on a global scale. Manufacturers must navigate complex regulatory environments, adapt to shifting market demands, and address potential risks related to intellectual property and supply chain disruptions. The complexity of these challenges increases when the requirements differ across regions, creating a fragmented landscape that can be difficult to manage.

While much has been written about the individual challenges posed by localization policies, there is a lack of comprehensive reviews that systematically examine these challenges and the strategic responses employed by medical device manufacturers. This review aims to fill this gap by synthesizing existing literature on the topic. The goal is to provide a thorough analysis of the challenges medical device companies face when complying with localization requirements, and to explore the strategies they adopt to mitigate these challenges. By reviewing the key studies in this area, this paper also seeks to offer insights into the evolving landscape of medical device localization, as well as to highlight potential areas for future research.

2. Overview of Localization Requirements in the Medical Device Industry

Localization requirements in the medical device industry refer to the set of regulations and policies that compel manufacturers to produce, assemble, or adapt medical devices within specific regions or countries [1]. These requirements are often imposed by governments or regulatory bodies as part of broader efforts to promote local industry development, ensure product safety, and reduce reliance on foreign suppliers. For medical device manufacturers, compliance with localization policies presents both opportunities and challenges, as they must balance the need for global market access with the demands of local production and regulation [2].

2.1. Definition and Objectives of Localization

Localization, in the context of medical devices, involves the modification of manufacturing, design, or distribution processes to comply with the specific requirements of a particular country or region. These requirements can vary significantly depending on the local regulatory environment, market conditions, and economic priorities. Common localization mandates include local manufacturing or assembly, adherence to national safety and quality standards, and the incorporation of region-specific technologies or materials [3].

The primary objectives of localization policies in the medical device industry are:

- 1) **Economic Growth and Job Creation:** Many governments view localization as a means to stimulate local economies by encouraging foreign and domestic companies to set up manufacturing facilities, which in turn creates jobs and fosters economic development.
- 2) **Regulatory Compliance and Safety Assurance:** Localization helps ensure that medical devices are produced in accordance with local regulatory standards, which are designed to meet the unique needs and risks of local healthcare systems. This can include compliance with standards related to product quality, labeling, packaging, and post-market surveillance.
- 3) **Reduction of Supply Chain Dependencies:** By requiring local production, governments aim to reduce their dependence on imports, which can be vulnerable to international trade disruptions. Local manufacturing ensures a steady and reliable supply of critical medical devices, especially in times of crisis such as pandemics or natural disasters.
- 4) **Technology Transfer and Skill Development:** Localization can also promote the transfer of technology and knowledge from global companies to local industries, improving the overall capabilities and expertise of the local workforce.

2.2. Global Trends in Localization Policies

Over the past few decades, there has been a significant shift towards more stringent localization policies in the medical device industry. These policies have evolved in response to various global and regional factors, such as economic growth, trade imbalances, and the increasing need for national self-sufficiency in healthcare supply chains [4,5].

- 1) **Increased Focus on Domestic Manufacturing:** Countries like China, India, and Brazil have implemented policies that encourage or mandate domestic production of medical devices. In these countries, local manufacturing is seen as a way to not only reduce reliance on imports but also to boost the domestic healthcare industry's competitiveness and technological capabilities.
- 2) **Stricter Regulatory Standards and Local Adaptation:** The European Union (EU) and the United States have also seen an increase in localization efforts, although the focus is often more on regulatory compliance. In the EU, the new Medical Device Regulation (MDR) requires manufacturers to meet stricter requirements for product certification and post-market surveillance, often necessitating local testing and adaptation. Similarly, the U.S. Food and Drug Administration (FDA) has established more stringent guidelines for the approval of locally manufactured medical devices, including additional inspections and certifications.
- 3) **Regional Trade Agreements and Their Impact on Localization:** Regional trade agreements such as the North American Free Trade Agreement (NAFTA) and the Trans-Pacific Partnership (TPP) have influenced localization policies by reducing barriers to trade while also encouraging local production in signatory countries. While these agreements have facilitated easier cross-border trade, they have also introduced new regulations that require localized manufacturing in some cases, particularly for medical devices that serve specific regional markets [6].
- 4) **Incentives and Tax Policies:** Governments in both developed and developing economies are offering incentives for manufacturers to localize their operations. These incentives can include tax breaks, subsidies, or preferential treatment in public procurement processes. In return, manufacturers are expected to contribute to local economic development, such as through job creation or infrastructure development.
- 5) **Impact of Global Health Crises:** The COVID-19 pandemic has underscored the vulnerabilities of global supply chains, prompting many countries to rethink their dependence on foreign-made medical devices. As a result, some nations have accelerated their localization policies, emphasizing the need for self-sufficiency in the production of critical healthcare products, including personal protective equipment (PPE) and diagnostic devices.

3. Challenges Posed by Localization Requirements

Localization requirements in the medical device industry present a range of challenges for manufacturers, particularly those that operate in multiple regions with differing regulations and market conditions. The complexity of these challenges varies depending on the country or region, but common issues include regulatory complexity, increased operational costs, intellectual property (IP) risks, and disruptions in the global supply chain. Each of these challenges not only affects the ability of manufacturers to comply with local regulations but also has broader implications for their competitiveness, profitability, and ability to innovate [7].

3.1. Regulatory Complexity

One of the most significant challenges posed by localization requirements is the regulatory complexity that manufacturers face when entering new markets. Different countries have their own regulatory frameworks governing the approval, certification, and post-market surveillance of medical devices [8]. These regulations may differ not only in terms of content but also in the procedures required for compliance. In some regions, medical devices are subject to highly stringent approval processes, such as clinical trials or testing to verify safety and efficacy, while in other regions, these processes may be less rigorous but still require significant adaptation to meet local standards [9].

For example, the European Union has its Medical Device Regulation (MDR), which imposes stricter requirements compared to the previous directive, particularly in areas of clinical evaluation and post-market surveillance. Similarly, in the United States, the FDA's 21st Century Cures Act introduced additional provisions related to medical device regulation, requiring more detailed documentation and reviews for devices manufactured locally [10].

The complexity increases when companies have to navigate multiple regulatory systems simultaneously. Local regulatory frameworks often require separate certifications for each market, leading to delays, costs, and sometimes contradictory requirements that can create confusion and increase compliance burdens [11].

3.2. Increased Costs

Localization of manufacturing and production processes typically leads to increased costs. These costs can arise from several factors, including the need to establish local manufacturing facilities, invest in specialized equipment, or modify production lines to meet local standards. Furthermore, the costs associated with regulatory compliance, such as paying for certifications, testing, and quality control, can add to the financial burden [12].

In addition, localization often necessitates higher labor costs, particularly in countries with higher wage standards. Manufacturers may need to hire and train a local workforce, which can be a time-consuming and costly process [13]. The cost of raw materials may also be higher in some regions due to tariffs, taxes, and import duties, further driving up production costs.

Table 1. summarizes some of the common cost factors associated with localization requirements:

Table 1. Key Cost Factors in Localization of Medical Device Manufacturing.

Cost Factor	Description	Impact
Regulatory Compliance Costs	Costs for certifications, testing, and meeting local regulatory requirements	High due to multiple certifications required per region
Labor Costs	Hiring and training local employees in manufacturing and quality control	Significant increase in wages in certain regions
Raw Material Costs	Higher prices for locally sourced materials or import taxes/tariffs	Increased due to local tariffs or supply shortages
Infrastructure Development	Cost to build or upgrade local manufacturing facilities	High capital expenditure

As shown in Table 1, localization introduces several cost factors that collectively increase operational expenses, making it more challenging for manufacturers to maintain profitability while adhering to local production requirements.

3.3. Intellectual Property (IP) Risks

When medical device manufacturers localize production, they often face heightened intellectual property (IP) risks. Localizing manufacturing can involve sharing sensitive designs, technologies, and trade secrets with local partners or government authorities. This increases the risk of intellectual property theft or misuse, particularly in regions with weaker IP protection laws or enforcement [14].

In some countries, manufacturers are required to share technical documentation, production processes, or even grant access to intellectual property as part of the local approval process. For instance, in markets like China, IP protection has historically been a concern for foreign companies, as local regulations may force foreign companies to partner with local entities, potentially exposing proprietary technology [15].

Furthermore, local competition can lead to a higher likelihood of IP infringement, as competitors may have access to similar technologies or innovations. Manufacturers need to carefully navigate local IP laws to ensure that their proprietary technologies remain protected while still complying with local regulations.

As indicated in Table 1, IP-related costs and risks are a major concern, and manufacturers must adopt strategies such as robust contractual agreements or local patent protections to mitigate these risks.

3.4. Supply Chain Disruptions

Localization of manufacturing processes may also result in supply chain disruptions. While localized production is intended to reduce dependency on foreign suppliers, it can lead to new challenges related to the sourcing of raw materials, components, and finished products. These disruptions are especially problematic in regions where the infrastructure is underdeveloped or where there are frequent fluctuations in the availability of materials.

Additionally, geopolitical tensions, trade policies, or unforeseen events such as the COVID-19 pandemic can disrupt the global supply chain and make it difficult for manufacturers to obtain critical components or maintain consistent production schedules. In some cases, even though production is localized, the supply of certain materials or technologies may still be dependent on imports, leading to delays and increased costs.

4. Strategic Responses to Localization Requirements

In response to the challenges posed by localization requirements, medical device manufacturers have developed several strategic approaches to maintain competitiveness and ensure compliance. These strategies aim to mitigate the risks associated with regulatory complexity, increased costs, and supply chain disruptions while taking advantage of the opportunities provided by local markets. Some of the most common strategic responses include building local partnerships, investing in local research and development (R&D), leveraging digital technologies, and engaging in advocacy efforts to influence policy and regulatory frameworks.

4.1. Building Local Partnerships

Building local partnerships is a key strategy for medical device manufacturers looking to navigate localization requirements effectively. Collaborating with local companies can provide several benefits, including access to local market knowledge, improved regulatory compliance, and cost-sharing opportunities. Local partnerships may include joint ventures, licensing agreements, or collaborations with local manufacturers, distributors, or healthcare providers.

By partnering with local entities, manufacturers can gain a better understanding of the regulatory landscape and adapt their products and processes to meet local requirements. Additionally, these partnerships can help facilitate market entry by leveraging the established networks and relationships of local partners. This approach can be particularly beneficial in regions with complex regulatory environments or where local knowledge is critical to success.

4.2. Investing in Local R&D

Investing in local research and development (R&D) is another strategic response to localization requirements. This approach not only helps manufacturers comply with local regulations but also enables them to tailor products to meet the specific needs of the local market. Local R&D investments can lead to the development of innovative products that are better suited to regional healthcare demands, such as devices designed for specific diseases or health conditions prevalent in the area.

Moreover, local R&D investments can help manufacturers stay ahead of regulatory changes by fostering close collaboration with local regulatory bodies and ensuring that

products are continuously updated to meet evolving standards. In many cases, local R&D can also lead to cost savings by optimizing designs and manufacturing processes to better align with local market conditions.

As shown in Table 2, investing in local R&D offers significant benefits for medical device manufacturers, from ensuring regulatory compliance to achieving cost efficiency and competitive advantage.

Table 2. Key Benefits of Investing in Local R&D.

Benefit	Description	Impact
Tailored Products	Ability to develop devices that meet the specific needs of the local population	Enhanced market acceptance and compliance
Regulatory Alignment	Ensures that products comply with local regulatory standards and expectations	Streamlined approval processes
Cost Efficiency	Reduces costs by designing products that align with local production capabilities	Lower manufacturing and testing costs
Competitive Advantage	Ability to introduce innovative solutions that address local healthcare challenges	Improved market positioning

4.3. Leveraging Digital Technologies

Leveraging digital technologies is a growing trend among medical device manufacturers as they respond to localization requirements. Digital technologies, including advanced manufacturing techniques, data analytics, and artificial intelligence (AI), can significantly enhance a company's ability to comply with local regulations while improving efficiency and innovation.

For instance, 3D printing and digital twins are revolutionizing the production of medical devices by allowing for faster prototyping and more customized designs that can meet local needs. Additionally, AI and machine learning are being used to optimize supply chains, reduce production costs, and improve product quality, all while ensuring that devices are manufactured in compliance with local regulations.

By adopting digital technologies, manufacturers can create more agile production processes, reduce reliance on traditional manufacturing techniques, and speed up the time-to-market for locally compliant devices. This approach is particularly valuable in markets where local regulations require frequent updates to devices or where demand for certain types of medical devices fluctuates rapidly.

4.4. Advocacy and Engagement

Finally, advocacy and engagement with local governments and regulatory bodies are essential strategies for manufacturers to influence localization requirements and shape the regulatory environment. Through lobbying efforts, industry associations, and public-private partnerships, manufacturers can contribute to the development of policies that are both conducive to local industry growth and aligned with global standards.

Engagement with policymakers helps manufacturers stay informed about upcoming changes in regulations and enables them to provide input on proposed policies that may affect their business operations. Furthermore, by participating in industry forums and collaborations, manufacturers can demonstrate their commitment to local economic development, which can enhance their reputation and build stronger relationships with stakeholders.

5. Case Studies

Case studies provide valuable insights into how medical device manufacturers have successfully navigated localization requirements and responded to the challenges discussed in previous sections. By examining real-world examples, we can identify effective

strategies and potential pitfalls in adapting to local markets and regulatory environments. This section will present several successful examples from different regions, followed by a discussion of the lessons learned from these experiences.

5.1. Successful Examples

There are numerous examples of medical device manufacturers who have successfully navigated the complexities of localization, each employing unique strategies to address local challenges while maintaining global competitiveness. These case studies illustrate how companies have adapted to regulatory requirements, minimized costs, and established strong market positions in local regions.

1) Example 1: Philips Healthcare in China

Philips Healthcare, a global leader in medical devices, has successfully localized its manufacturing operations in China. The company established a local production facility that not only manufactures products tailored to the Chinese market but also complies with the stringent Chinese regulatory environment. Philips' strategy included forming partnerships with local suppliers and regulatory bodies to streamline the approval process for their products.

The company also invested in local research and development (R&D) to design products that meet the specific healthcare needs of the Chinese population, such as devices focused on chronic disease management, which is a growing concern in China. As a result, Philips has become one of the top medical device suppliers in the Chinese market, with a significant share of the local market.

2) Example 2: Medtronic's Manufacturing in India

Medtronic, a leading global medical device company, has made significant strides in India by setting up a local manufacturing facility. This facility not only serves the Indian market but also produces devices for export to neighboring countries in Asia. Medtronic's strategy of investing in local R&D and building a network of local suppliers has enabled the company to reduce costs and increase efficiency.

Medtronic also took a proactive approach in engaging with the Indian government to navigate the regulatory landscape. By partnering with local healthcare providers and academic institutions, the company ensured that its devices were well-suited to the needs of Indian patients while complying with local regulatory requirements.

3) Example 3: Siemens Healthineers in the Middle East

Siemens Healthineers, a division of Siemens AG, has successfully localized its operations in the Middle East by establishing a research and manufacturing hub in the United Arab Emirates (UAE). This hub focuses on creating products specifically designed for the healthcare needs of the region, such as advanced imaging technologies for diagnostic purposes.

The company has been able to leverage its strong local partnerships with healthcare institutions and regulatory bodies to ensure that its products meet the required standards and are accepted in the market. Siemens Healthineers' approach of investing in local talent and building a robust supply chain has allowed them to stay competitive in the rapidly growing healthcare market in the Middle East.

5.2. Lessons Learned

While the case studies above highlight successful examples, they also provide important lessons for other medical device manufacturers considering localization as a strategy. These lessons can help companies avoid common pitfalls and make informed decisions when entering new markets.

1) Lesson 1: Importance of Local Partnerships

One of the key takeaways from these case studies is the importance of forming strong local partnerships. Both Philips and Medtronic demonstrated the value of collaborating with local suppliers, distributors, and regulatory bodies to ensure smooth market entry.

These partnerships can help companies navigate complex regulatory environments, reduce time-to-market, and improve product acceptance in the local market.

2) Lesson 2: Tailoring Products to Local Needs

Another crucial lesson is the need to tailor products to the specific healthcare needs of local populations. Philips' success in China and Siemens Healthineers' approach in the Middle East highlight how investing in local R&D and designing products that address regional health challenges can significantly increase market acceptance and customer loyalty. Localized products that cater to local needs not only enhance regulatory compliance but also help companies differentiate themselves in competitive markets.

3) Lesson 3: Regulatory Engagement is Key

Navigating local regulatory environments is one of the biggest challenges manufacturers faces when localizing. Engaging with local regulatory bodies early in the process can help manufacturers understand the requirements and avoid delays in product approvals. Medtronic's proactive engagement with the Indian government exemplifies how early collaboration can facilitate smoother market entry and help companies anticipate regulatory changes.

4) Lesson 4: Managing Costs through Local Production

The importance of managing costs through local production cannot be overstated. All three examples demonstrate how local manufacturing can reduce supply chain costs, lower tariffs, and ensure faster product availability. However, companies must also balance the initial investment in local production with long-term cost savings to ensure the financial viability of the strategy.

5) Lesson 5: Adapting to Local Market Dynamics

Finally, companies must remain adaptable to the dynamic nature of local markets. Economic fluctuations, changes in government policies, or unforeseen events like the COVID-19 pandemic can disrupt localization strategies. Manufacturers must build resilient operations that can quickly adapt to these changes without compromising on product quality or market competitiveness.

6. Conclusion and Recommendations

6.1. Summary of Findings

This paper has explored the growing challenges and strategic responses to localization requirements faced by medical device manufacturers in the global marketplace. As nations increasingly adopt localization policies to promote domestic manufacturing, medical device companies must navigate a complex landscape of regulatory demands, supply chain issues, and rising operational costs.

The key challenges identified in this study include regulatory complexity, increased manufacturing and compliance costs, intellectual property (IP) risks, and disruptions to supply chains. Manufacturers must also contend with the need for products that are tailored to meet local market demands while maintaining global product standards.

In response to these challenges, medical device companies have adopted a range of strategic approaches. These include building local partnerships to improve market access and regulatory compliance, investing in local research and development (R&D) to better address regional healthcare needs, leveraging digital technologies to enhance operational efficiency, and engaging in advocacy efforts to influence favorable policy changes. Successful examples, such as Philips Healthcare's operations in China, Medtronic's manufacturing facility in India, and Siemens Healthineers' hub in the UAE, demonstrate how localization strategies can be effectively implemented to ensure compliance and enhance market competitiveness.

Overall, the findings underscore the importance of strategic localization as a means to both overcome challenges and capitalize on new opportunities in a rapidly evolving global healthcare market.

6.2. Recommendations

Based on the findings of this paper, several key recommendations can be made for medical device manufacturers looking to successfully navigate localization requirements:

- 1) **Strengthen Local Partnerships:** Medical device manufacturers should prioritize forming strategic partnerships with local companies, suppliers, and regulatory bodies. These partnerships can help companies better understand local market dynamics, improve regulatory compliance, and reduce operational risks. Establishing strong local networks can also streamline the approval process and facilitate smoother market entry.
- 2) **Invest in Local R&D:** Investment in local R&D is critical for tailoring products to meet the unique healthcare needs of regional populations. Companies should focus on establishing local R&D centers that can not only innovate but also ensure that their products meet local regulatory standards. Local R&D investments also provide the opportunity to leverage region-specific insights and create products that address prevalent health issues in the area.
- 3) **Leverage Digital Technologies:** Manufacturers should actively adopt digital technologies such as 3D printing, AI, and advanced data analytics to improve manufacturing processes and streamline supply chain management. Digital tools can help companies reduce costs, improve product quality, and enhance speed-to-market, all while ensuring compliance with local regulations. Leveraging digital technologies will also enhance the flexibility and agility of production systems, making them better suited to meet rapidly changing local market demands.
- 4) **Engage in Proactive Policy Advocacy:** Manufacturers should engage with local governments and industry bodies to advocate for favorable regulatory policies that support local manufacturing and innovation. Proactively participating in policy discussions can help shape regulations that are aligned with both local market needs and global standards. Manufacturers should also work to stay informed about upcoming regulatory changes to avoid compliance issues.
- 5) **Adopt a Flexible Localization Strategy:** Given the dynamic nature of regulatory environments, manufacturers should adopt a flexible localization strategy that can quickly adapt to changes in market conditions, economic shifts, and new regulations. A resilient localization strategy should include contingency plans that address potential supply chain disruptions, changes in political climates, and unforeseen challenges such as pandemics or economic downturns.
- 6) **Monitor Global Trends:** Lastly, manufacturers should continuously monitor global trends in localization policies and emerging markets. By staying ahead of policy changes and identifying new opportunities for expansion, companies can ensure that their localization efforts are aligned with long-term strategic goals.

By following these recommendations, medical device manufacturers can successfully navigate the complexities of localization and strengthen their position in both local and global markets.

References

1. A. Ghanbarzadeh, A. Mirzazadeh, R. Tavakkoli-Moghaddam, and Z. Molamohamadi, "Optimization of a sustainable supply chain for medical device industry under uncertainty and COVID-19 pandemic," *Ann. Oper. Res.*, vol. 1, pp. 1–37, 2024, doi: 10.1007/s10479-024-06370-1.
2. T. Senapati, A. Sarkar, and G. Chen, "Enhancing healthcare supply chain management through artificial intelligence-driven group decision-making with Sugeno–Weber triangular norms in a dual hesitant q-rung orthopair fuzzy context," *Eng. Appl. Artif. Intell.*, vol. 135, p. 108794, 2024, doi: 10.1016/j.engappai.2024.108794.
3. O. Bak, A. Braganza, and W. Chen, "Exploring blockchain implementation challenges in the context of healthcare supply chain (HCSC)," *Int. J. Prod. Res.*, vol. 63, no. 2, pp. 687–702, 2025, doi: 10.1080/00207543.2023.2286491.
4. W. Akram et al., "Blockchain technology: A potential tool for the management of pharma supply chain," *Res. Soc. Admin. Pharm.*, vol. 20, no. 6, pp. 156–164, 2024, doi: 10.1016/j.sapharm.2024.02.014.

5. H. Jahani, Y. Khosravi, B. Kargar, K. L. Ong, and S. Arisian, "Exploring the role of drones and UAVs in logistics and supply chain management: a novel text-based literature review," *Int. J. Prod. Res.*, vol. 63, no. 5, pp. 1873–1897, 2025, doi: 10.1080/00207543.2024.2373425.
6. K. Kioskli et al., "A risk and conformity assessment framework to ensure security and resilience of healthcare systems and medical supply chain," *Int. J. Inf. Secur.*, vol. 24, no. 2, pp. 1–28, 2025, doi: 10.1007/s10207-025-01009-z.
7. V. V. Kumar, A. Sahoo, S. K. Balasubramanian, and S. Gholston, "Mitigating healthcare supply chain challenges under disaster conditions: a holistic AI-based analysis of social media data," *Int. J. Prod. Res.*, vol. 63, no. 2, pp. 779–797, 2025, doi: 10.1080/00207543.2024.2316884.
8. A. Adhikari, R. Joshi, and S. Basu, "Collaboration and coordination strategies for a multi-level AI-enabled healthcare supply chain under disaster," *Int. J. Prod. Res.*, vol. 63, no. 2, pp. 497–523, 2025, doi: 10.1080/00207543.2023.2252933.
9. I. Zrelli et al., "Drone applications in logistics and supply chain management: a systematic review using latent Dirichlet allocation," *Arab. J. Sci. Eng.*, vol. 49, no. 9, pp. 12411–12430, 2024, doi: 10.1007/s13369-023-08681-0.
10. A. Y. A. B. Ahmad et al., "An IoT and blockchain-based secure and transparent supply chain management framework in smart cities using optimal queue model," *IEEE Access*, vol. 12, pp. 51752–51771, 2024, doi: 10.1109/ACCESS.2024.3376605.
11. N. Louissaint and D. Ekoma, "Securing the backbone of healthcare: Resilience in the pharmaceutical supply chain," *J. Crit. Infrastruct. Policy*, vol. 6, no. 1, p. e12036, 2025, doi: 10.1002/jci3.12036.
12. M. Tiwari et al., "Modelling supply chain visibility, digital technologies, environmental dynamism and healthcare supply chain resilience: An organisation information processing theory perspective," *Transp. Res. Part E: Logist. Transp. Rev.*, vol. 188, p. 103613, 2024, doi: 10.1016/j.tre.2024.103613.
13. N. Alemsan et al., "Integrating lean and resilience: a healthcare supply chain perspective," *Int. J. Ind. Eng. Oper. Manag.*, 2025, doi: 10.1108/IJIEOM-11-2024-0076.
14. E. I. Vazquez Melendez, P. Bergey, and B. Smith, "Blockchain technology for supply chain provenance: increasing supply chain efficiency and consumer trust," *Supply Chain Manag.: Int. J.*, vol. 29, no. 4, pp. 706–730, 2024, doi: 10.1108/SCM-08-2023-0383.
15. E. Javanmardi, P. Maresova, N. Xie, and R. Mierzwiak, "Exploring business models for managing uncertainty in healthcare, medical devices, and biotechnology industries," *Heliyon*, vol. 10, no. 4, 2024, doi: 10.1016/j.heliyon.2024.e25962.

Disclaimer/Publisher's Note: The views, opinions, and data expressed in all publications are solely those of the individual author(s) and contributor(s) and do not necessarily reflect the views of PAP and/or the editor(s). PAP and/or the editor(s) disclaim any responsibility for any injury to individuals or damage to property arising from the ideas, methods, instructions, or products mentioned in the content.